Antibiotic Resistance is a serious and eminent threat to public health. Bacteria are acquiring resistance to all available antibiotics at a much faster rate than the introduction of new drugs. Researchers estimate that by the year 2050, drug-resistant bacteria will cause more than 10 million deaths and cost the global economy an excess of $100 trillion annually.
Omnix's technology is based on the innate immune system of specific insects combating bacteria in their surroundings. These insects use antimicrobial peptides (AMPs) which physically damage the bacterial membrane with no toxic effect to eukaryotic cells. This strategy has been proven very efficient for the past 250 million years. The peptides' unique mechanism of action makes it very difficult for bacteria to develop resistance or tolerance.
Today, the major obstacle barring the use of these peptides, is their high sensitivity to proteolytic degradation which renders them unstable and has hindered them for therapeutic applications.
Omnix's proprietary technology utilizes genetic engineering to overcome this instability and enable the synthesis of soluble, stable, safe and highly potent novel antimicrobial peptides. Our unique technology allows for a vast array of peptides to be designed for further therapeutic use.